Experts suggest that other countries, including the U.S., may follow a similar path, given the increasing evidence supporting psychedelics' effectiveness in treating mental health conditions like PTSD, depression, addiction, and eating disorders.

The U.S. nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) completed a second phase-three trial on MDMA as a treatment for PTSD in November 2022, paving the way for potential FDA approval by 2024. Psilocybin research is also progressing, with a recent phase-two trial showing positive results for treatment-resistant depression.

Australia's approval of these drugs might expedite the approval process in the U.S. and elsewhere, as regulators often seek precedents before making decisions.

While some U.S. states have already legalized psilocybin use, Australia will be the first country to make psychedelics available for medicinal use at a national level, starting July 1. However, access won't be as straightforward as traditional prescription medications, as authorized psychiatrists need to navigate a specific process for prescribing these unapproved substances.

While the advancements in psychedelics research are promising, experts emphasize the importance of balanced enthusiasm and rigorous science. Adequate therapist training is crucial, as the drug's effectiveness hinges on the therapeutic approach.

Australia's decision could set a precedent globally, impacting how other countries approach psychedelic medicines for mental health treatment. As the world watches, careful consideration and evidence-based practices are essential to ensure the responsible use and potential benefits of these substances.